Vaccine Manufacturing Plant Uses Standardized Production Management Software - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Vaccine Manufacturing Plant Uses Standardized Production Management Software


The Japanese biotech company Unigen implemented Werum's PAS-X Manufacturing Execution System (MES) in only four months at the company's greenfield site in Gifu, Japan, Werum reported in a press release. Unigen is a joint venture of the Japanese pharmaceutical company UMN Pharma and the heavy equipment manufacturer IHI Corporation. The plant is one of the largest for production of recombinant influenza vaccines and contract manufacturing of biopharmaceutical products that accommodates several bioreactors, each with a capacity of 21,000 liters.

At the new plant, Unigen uses a complex biopharmaceutical manufacturing process called Baculovirus Expression Vector System. For this process, Unigen required standardized production management software that is able to meet high quality and compliance standards in accordance with the Japanese zero-error tolerance. The short implementation time was possible because the MES program is standardized and was implemented using Werum’s four-phased fast-track implementation methodology: Ready, Fit, Build, and Run. PAS-X was delivered with the entire user interface in Japanese. Werum carried out this project in close cooperation with their Japanese partner, CST Chiyoda System Technologies Corporation.

Source: Werum

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here